Minimally Invasive Thoracic Surgery Market Report 2025

The minimally invasive thoracic surgery market size has grown strongly in recent years. It will grow from $4.04 billion in 2024 to $4.38 billion in 2025 at a compound annual growth rate (CAGR) of 8.4%. The growth during the historic period can be attributed to the rising prevalence of lung cancer and other thoracic disorders, increasing adoption of robotic-assisted thoracic procedures, an expanding geriatric population, greater patient awareness, and rising healthcare expenditures.

The minimally invasive thoracic surgery market size is expected to see strong growth in the next few years. It will grow to $5.98 billion in 2029 at a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be attributed to the increasing demand for shorter hospital stays, greater integration of advanced imaging and navigation technologies, rising surgeon preference, growing government and private funding, and an increased focus on value-based healthcare models. Key trends in the forecast period include advancements in robotic-assisted surgical platforms, improvements in minimally invasive instrumentation design, integration of artificial intelligence, incorporation of augmented and virtual reality tools, and technological innovations in 3D and 4K imaging systems.

The rising prevalence of lung diseases is expected to drive the growth of the minimally invasive thoracic surgery market in the coming years. Lung diseases, including asthma, COPD, pneumonia, and lung cancer, impair lung function and breathing. The increase in lung disease cases is largely attributed to tobacco smoking, as harmful chemicals in tobacco damage lung cell DNA over time, increasing the risk of uncontrolled cell growth and tumor formation. Minimally invasive thoracic surgery benefits patients by removing or destroying tumors through small incisions or imaging-guided probes, which shortens recovery time, minimizes damage to healthy lung tissue, reduces complications, and allows patients to resume normal activities sooner. For example, in June 2025, the Centers for Disease Control and Prevention reported that the United States recorded 218,893 new cases of lung cancer in 2022, and lung cancer caused 131,584 deaths in 2023. Consequently, the rising incidence of lung diseases is fueling the minimally invasive thoracic surgery market.

Companies in the minimally invasive thoracic surgery market are increasingly developing advanced technologies, such as robotic-assisted surgery platforms, to improve surgical precision and overall patient outcomes. Robotic-assisted surgery systems allow surgeons to control robotic arms during procedures, providing enhanced accuracy, dexterity, and visualization compared to traditional surgery. For instance, in June 2024, Monmouth Medical Centre in the U.S. introduced the Ion Robotic platform, the Aliya PEF system, and intraoperative AI-driven CT imaging. These technologies offer improved surgical precision, real-time imaging for better decision-making, and minimally invasive lung cancer diagnosis and treatment with faster recovery. They also provide real-time navigation, non-thermal tumor ablation, and reduced radiation exposure, supporting early detection and effective care.

In August 2024, KARL STORZ Endoscopy America Inc., a U.S.-based endoscopic equipment provider, acquired Asensus Surgical Inc. for \$0.35 per share in cash. Through this acquisition, KARL STORZ aims to strengthen its capabilities in digital and robotic-assisted minimally invasive thoracic surgery by integrating advanced performance-guided surgical platforms. Asensus Surgical Inc., a U.S.-based medical device company, specializes in robotic-assisted platforms for minimally invasive thoracic procedures.

Major players in the minimally invasive thoracic surgery market are Johnson And Johnson Services Inc., Medtronic Plc, Koninklijke Philips N.V., Stryker Corporation, GE Healthcare Inc., Olympus Corporation, Intuitive Surgical Operations Inc., Smith & Nephew plc, Teleflex Incorporated, Karl Storz SE & Co. KG, Cook Group Incorporated, CONMED Corporation, NuVasive Inc., Applied Medical Resources Corporation, KLS Martin Group, Aesculap Inc., Medela Inc., Richard Wolf GmbH, B. Braun Melsungen AG, Ackermann Instrumente GmbH, Cmr Surgical, Genesee Biomedical Inc.

North America was the largest region in the minimally invasive thoracic surgery market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in minimally invasive thoracic surgery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the minimally invasive thoracic surgery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

Minimally invasive thoracic surgery (MITS) is a surgical approach that performs chest operations through small incisions using specialized instruments, aiming to minimize bodily trauma and postoperative discomfort. This technique shortens hospital stays, accelerates recovery, and provides enhanced precision and visibility compared to traditional open surgery, ultimately improving surgical outcomes and reducing complications.

The primary types of minimally invasive thoracic surgery include lobectomy, wedge resection, pneumonectomy, and others. A lobectomy is a surgical procedure that removes an entire lobe of an organ, most commonly the lung, to treat disease or damage. MITS utilizes various products such as energy devices, surgical instruments, staplers and disposables, and visualization systems, with procedural methods including video-assisted thoracoscopic surgery (VATS), robotic-assisted thoracic surgery, endoscopic thoracic surgery, and others. These procedures are applied in different areas, including lung cancer surgery, esophageal surgery, mediastinal surgery, and more, and are utilized by end users such as hospitals, specialty clinics, ambulatory surgical centers, and others.

The minimally invasive thoracic surgery market research report is one of a series of new reports that provides minimally invasive thoracic surgery market statistics, including minimally invasive thoracic surgery industry global market size, regional shares, competitors with a minimally invasive thoracic surgery market share, detailed minimally invasive thoracic surgery market segments, market trends and opportunities, and any further data you may need to thrive in the minimally invasive thoracic surgery industry. This minimally invasive thoracic surgery market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The minimally invasive thoracic surgery (MITS) market consists of revenues earned by entities by providing services such as diagnostic endoscopy, preoperative imaging, intraoperative navigation support, postoperative care coordination, and tele-consultation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimally invasive thoracic surgery market also includes sales of energy-based dissection devices, robotic surgical arms, single-use staplers, and ultrasound-guided instrument accessories. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.